Updating results

93 results for kidney cancer

Sort: Relevance | Date

Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma [ID1426]

In development [GID-TA10331] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Renal cancer

Everything NICE has said on renal (kidney) cancer in an interactive flowchart

NICE Pathway Published December 2013 Last updated May 2019

Irreversible electroporation for treating renal cancer (IPG443)

Evidence-based recommendations on irreversible electroporation (IRE) for treating renal (kidney) cancer

Interventional procedures guidance Published February 2013

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)

Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy; keyhole surgery to remove a kidney)

Interventional procedures guidance Published August 2005

Acute kidney injury (QS76)

This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. Acute kidney injury is sudden damage to the kidneys, which can sometimes result in kidney failure. The quality standard includes assessment by non-specialists and when to refer to specialist services. It describes high-quality care in priority areas for improvement.

Quality standard Published December 2014

Kidney conditions

Everything NICE has said on kidney (renal) conditions in an interactive flowchart

NICE Pathway Published May 2015 Last updated May 2018

Percutaneous cryotherapy for renal cancer (IPG402)

Evidence-based recommendations on percutaneous cryotherapy for renal (kidney) cancer

Interventional procedures guidance Published July 2011

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Technology appraisal guidance Published February 2017

Urinary incontinence in neurological disease: assessment and management (CG148)

This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

Clinical guideline Published August 2012

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published August 2017

Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the first-line treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published September 2009

Percutaneous radiofrequency ablation for renal cancer (IPG353)

Evidence-based recommendations on percutaneous radiofrequency ablation for treating renal (kidney) cancer

Interventional procedures guidance Published July 2010

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

Technology appraisal guidance Published November 2017

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published November 2016

Tivozanib for treating advanced renal cell carcinoma (TA512)

Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published March 2018

Neutropenic sepsis: prevention and management in people with cancer (CG151)

This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

Clinical guideline Published September 2012

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

Technology appraisal guidance Published November 2017

Laparoscopic partial nephrectomy (IPG151)

Evidence-based recommendations on laparoscopic partial nephrectomy (keyhole surgery to remove kidney tumours)

Interventional procedures guidance Published January 2006

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published January 2018

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

Evidence-based recommendations on topotecan (Hycamtin) for treating recurrent stage IVB (stage 4B) cervical cancer (cancer of the cervix)

Technology appraisal guidance Published October 2009

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed

Technology appraisal guidance Published February 2015

Urogenital conditions

Everything NICE has said on urogenital conditions in an interactive flowchart

NICE Pathway Published June 2015 Last updated November 2019

Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)

Technology appraisal guidance Published January 2008

Irreversible electroporation for treating liver metastases (IPG445)

Evidence-based recommendations on irreversible electroporation (IRE) for treating liver metastases (secondary cancers)

Interventional procedures guidance Published February 2013

Intravenous fluid therapy in children and young people in hospital (NG29)

This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.

NICE guideline Published December 2015

Non-Hodgkin's lymphoma: diagnosis and management (NG52)

This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

NICE guideline Published July 2016

Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)

Technology appraisal guidance Published February 2010

Laparoscopic cryotherapy for renal cancer (IPG405)

Evidence-based recommendations on laparoscopic cryotherapy (keyhole surgery to destroy cancer cells by freezing) for treating renal (kidney) cancer

Interventional procedures guidance Published August 2011

Bladder cancer: diagnosis and management (NG2)

This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

NICE guideline Published February 2015

Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

Evidence-based recommendations on irreversible electroporation (IRE) for treating primary lung cancer and metastases in the lung

Interventional procedures guidance Published February 2013

Type 2 diabetes in adults: management (NG28)

This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

NICE guideline Published December 2015 Last updated August 2019

Sepsis

Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart

NICE Pathway Published July 2016 Last updated January 2020

Haematological cancers: improving outcomes (NG47)

This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.

NICE guideline Published May 2016

Sepsis: recognition, diagnosis and early management (NG51)

This guideline covers the recognition, diagnosis and early management of sepsis for all populations. The guideline committee identified that the key issues to be included were: recognition and early assessment, diagnostic and prognostic value of blood markers for sepsis, initial treatment, escalating care, identifying the source of infection, early monitoring, information and support for patients and carers, and training and education.

NICE guideline Published July 2016 Last updated September 2017

Pancreatitis (NG104)

This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

NICE guideline Published September 2018

Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

NICE guideline Published July 2016

Myeloma: diagnosis and management (NG35)

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

NICE guideline Published February 2016 Last updated October 2018

The NGAL Test for early diagnosis of acute kidney injury (MIB3)

Advice on the use of the NGAL Test for early diagnosis of acute kidney injury (AKI) to aid local decision-making

Medtech innovation briefing Published February 2014

Past appeals and decisions

galantamine and memantine (review) 13-14 August 2006 TA142 Anaemia (cancer-treatment induced) - Erythropoetin (alpha and beta) and...

Published May 2019 Last updated May 2019

Minimally invasive video‑assisted parathyroidectomy (IPG501)

Evidence-based recommendations on minimally invasive (keyhole) video-assisted parathyroidectomy to remove abnormal parathyroid glands

Interventional procedures guidance Published August 2014

NICE Clinical guidelines list

The complete list of clinical guidelines published by NICE.

Shared learning award winners and finalists

Winners and finalists of our Shared Learning awards

Published June 2019 Last updated June 2019

NICE Diagnostics guidance list

The complete list of diagnostics guidance published by NICE.

Shared learning awards previous winners and finalists

breathlessness and COPD (MISSION ABC) Linking NICE acute kidney injury quality standards with Think Kidneys resources...

Published June 2019 Last updated June 2019

Venous thromboembolism

Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart

NICE Pathway Published May 2011 Last updated December 2019

Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel

Diagnostics guidance Published October 2013

NICE Key therapeutic topics list

The complete list of key therapeutic topics published by NICE.

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

NICE guideline Published March 2018 Last updated August 2019